lyle mcdonald glp-1 A few years ago it became clear to me that the GLP-1s were not only here to stay but, despite fitness industry hardheadeness, represented the first truly new development in the treatment Realities of life on GLP-1s

Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

While animal and early human studies indicate possible roles in adipose regulation, the compound remains under investigation across several scientific fields

and JANSEN, B., 2016

Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

The newer, longer-acting versions like Ozempic and Wegovy were approved more recently (Ozempic in 2017, Wegovy in 2021), but theyve been studied in large clinical trials involving thousands of patients over several years